Executive Search Rx Specialty Pharma
The industry's capital has shifted massively into specialized therapies. The grace period for price setting has been halved to six months since the German Statutory Health Insurance (GKV) Financial Stabilization Act. An unfilled position during this critical phase costs real money every day. We fill your key strategic positions precisely and discreetly. Exclusive headhunting in Germany for profiles in medical affairs, marketing, and sales. Genuine risk management for your P&L.
Market mechanics and the pressure of the capital markets
Industrial portfolios are undergoing fundamental restructuring. This development is being driven by massive pressure from shareholders. Investors today demand clear pure play strategies. They no longer want conglomerates. The market punishes unclear profiles with a massive valuation discount.
Focus on Pure Play and Innovation
Economically, the market is divided into low-margin volume business and high-priced innovations. Investors demand a clear separation. They want to decide for themselves whether to invest in stable volume business or risky innovation. Research-based pharmaceutical companies have drawn the obvious conclusion. They have consistently spun off their high-volume business to protect their core margins. Novartis has successfully floated Sandoz on the stock exchange. Johnson & Johnson has spun off Kenvue. Sanofi has completed its exit from Opella. The focus of these corporations is now entirely on high-margin specialty care. Any vacancy in this segment immediately becomes a topic for the board. Delays in launch jeopardize commitments to analysts and thus the share price.
Primary Care
and the volume business
Primary Care refers to basic medical care. From an economic perspective, this market today is dominated by generics logic. It is governed by aggressive rebate contracts. This is a pure volume business focused on supply chain and tender management. A single field sales visit to a physician in Germany today costs between 150 and 200 euros. With an average daily therapy cost of just a few cents, this simply no longer pays off. There are rare exceptions. True blockbusters like Wegovy from Novo Nordisk or Zepbound from Eli Lilly for obesity treatment form lucrative pockets of innovation. These products fall under the lifestyle provision of the German Social Code (SGB V). Statutory health insurers still do not reimburse the costs. Patients pay for these therapies out of pocket. For manufacturers, this means full margins without AMNOG pricing pressure. Modern RSV vaccines also defend high margins in the primary care market.
Specialty Care
and the ticking clock
This is where your growth lies. Biopharmaceuticals now account for well over 33 percent of total German market sales. Capital is flowing into oncology, immunology, and rare diseases. But the pressure on profitability is extreme from two sides. At launch, the law halves the grace period. After six months, free pricing is over. At the same time, the AMNOG sales threshold for orphan drugs has been capped at 30 million euros. Successful niche products suddenly fall under full evaluation. At the same time, the clock is ticking at the end of the life cycle. Patent expiry threatens the industry's existential sales. Giants such as AbbVie's Humira have long since lost their exclusivity. They are feeling the massive loss of margins due to biosimilars. Bayer's Eylea lost its protection in Europe in 2025. Biosimilars are now aggressively occupying the market. For MSD's Keytruda, the huge patent cliff in 2028 is looming ever closer. Those who lead here must compensate for enormous sales slumps by building new pipelines. The remaining exclusivity period of the current cash cows must be defended relentlessly.
bottlenecks
in strategy implementation
Every day, we see why launches fail. It's usually not because of a lack of global strategy. It's because there aren't the right people to implement it.
Medical Affairs
Your key opinion leaders demand tough scientific discussions about real-world evidence. We fill positions with medical directors and senior medical science liaisons. These experts build trust with medical specialists on an equal footing. This happens long before the product is on the market. Without an excellent medical team, your sales team will later find themselves facing closed doors.
Marketing and Launch Excellence: Farewell to yesterday
The days when a launch was controlled solely by the frequency of the sales force are over. We often hear the phrase “We've always done it this way” in specialist departments. This mentality will not get you anywhere in the new reality. Today's medical specialists demand a seamless omnichannel strategy. They want information on demand and via digital channels that do not interfere with their daily medical practice. Today, profiles that combine regulatory compliance and innovation are in demand. The courage to seize opportunities within strict compliance requirements is becoming a decisive competitive advantage. We find Head of Marketing and Senior Product Manager candidates who can orchestrate specialty launches in a modern way. These executives are proficient in agile content management and break through internal approval bottlenecks. Those who still think in silos today are losing touch with their target audience.
Commercial Leadership and Individual Contributors
The decision-making center for specialty products has shifted dramatically. Traditional sales in the doctor's office are losing ground. Over 50 percent of specialists now refuse access for conventional visits. Today, the relevant discussions take place in the office of the commercial management. It's all about budgets and supply contracts. We find the experts for strategic key account management for you. These profiles negotiate on an equal footing with hospital networks and purchasing groups. At the same time, we recruit executives and high-impact experts for your international scaling. This shows how a single appointment can move your P&L. We are accompanying the profound change among top talent. More and more high performers are rejecting traditional leadership roles. They define themselves not by FTE but by measurable impact. These individual contributors are often solely responsible for portfolios worth up to €100 million. They want to shape things. The leverage is enormous. Unfilled positions cost millions.
The heterogeneous talent market in the pharmaceutical industry & the reality of vacancies
There is no such thing as a single “pharmaceutical job market.” This has always been true for the different markets—Rx Specialty, OTC Consumer, CDMO, and Biotech. The respective market mechanisms are too different. However, talent markets also differ within a market segment, especially in the specialty pharma sector.
To understand this, you have to follow the money. As a general rule, demand for personnel moves in line with the flow of capital, with a time lag of approximately 6-9 months. Where money is withdrawn, jobs will be cut sooner or later. This could be observed, for example, in the waves of restructuring in the sales teams for broad indications. Where capital flows in, there is demand for qualified specialists and managers. We are seeing high demand for qualified specialists and managers, particularly in the fields of oncology, immunology, and rare diseases in general. This is where money is still being made. Due to the $30 million sales threshold for rare diseases, we expect demand to be subdued in the short to medium term. The new regulation will undoubtedly influence investment decisions. Regardless of the indication, the clock is ticking relentlessly for every patent. Once protection expires, there is a risk of an 80% drop in price. Companies do not have time for long start-up phases.
The problem is that the qualifications of the workers who are becoming available, whether managers or specialists, often do not match the new challenges. Although the market has eased overall for employers, it is highly competitive for key positions of the future. Demographic change is acting as an accelerant.
Candidates with the right skills determine the attractiveness of the company. A vacancy in roles critical to success is not purely an HR problem. It is a threat to the P&L. The industry standard time for filling a vacancy in the pharmaceutical sector is over 150 days. That is almost the entire window of your free pricing.
What do unfilled positions really cost? Our own analyses of the economic impact specifically for German pharmaceutical companies were published in the trade journal pm report. They show revenue losses in the millions. Every week without the right expert delays market access. This reduces your profits in the long term. Today's top performers are looking for purpose and self-efficacy. They want to see real social added value. This clientele is not actively looking. We secure access to these passive talents through market depth and discretion. In an environment where traditional recruiting approaches are hardly effective anymore, personal dialogue is the only way.
Examples of mandates in specialty pharma
To understand the market dynamics of individual pharmaceutical sub-sectors, one must have a thorough understanding of their respective job markets. But that alone won't solve a staffing shortage. Our pharmaceutical executive search approach will. A nearly classic example from our practice illustrates the challenge in the sales of prescription specialty pharmaceuticals. A long-standing sales force was hindering modernization towards omnichannel approaches. Declining access to physicians demanded entirely new sales strategies. Through targeted strategic thinking, we identified and placed a Head of Marketing from a structurally similar specialist market. The result was a successful reframing of the collaboration. The digital strategy was deeply embraced by the entire team. Read the details of this prescription specialty pharmaceutical business case here.
Our Executive Search Approach
We refrain from making loud promises and mass processing. We analyze your individual bottleneck and go directly to the market. As a specialized boutique, we identify the best minds in medical affairs, marketing, and sales in the specialty pharma sector and approach them with absolute discretion and on an equal footing. Our aptitude diagnostics separate the theorists from the doers.
We check specifically whether medical advisors have the necessary KOL network. We clarify in depth whether senior product managers can really manage a fast-track launch. We question whether marketing heads can secure sustainable access to medical specialists through a smart multichannel strategy.
We closely monitor the entire process. This is how we ensure your growth and minimize the risk of expensive misplacements. Let's find out in a personal conversation which recruiting strategy is most suitable for you.
Frequently Asked Questions in the Specialty Pharmaceuticals Sector
We're not starting from scratch. We leverage an established network, continuously map the market, and anticipate market changes. Through our exclusive direct search, we reach precisely the individuals who are a good professional fit and open to new opportunities.
Access to medical professionals is becoming noticeably more restricted. At the same time, the level of technical complexity is increasing dramatically. Simply presenting a good product is no longer sufficient. Pharmaceutical companies must now position themselves as true strategic partners. They must offer clear added value beyond the product itself.
Managers must be able to develop an omnichannel strategy that solves the healthcare provider access problem. Long-term employees must be included in the transformation to a modern structure. This requires sensitivity to avoid overwhelming the workforce (and the works council). Specialized key account managers must understand their target group down to the smallest detail and be able to communicate and persuade the chief physician and the administrative director on equal footing. They must be familiar with the actual needs on the ground. Successful approaches today include concrete projects that make the daily work of medical professionals easier.
We act as your extended arm in the market. All communication is completely confidential. Your company name will only be revealed once our fundamental interest and professional qualifications have been unequivocally established.
We use state-of-the-art technology. This makes us efficient. But the algorithm doesn't understand human nuances. We focus on in-depth expertise and personal connection instead of mindless keyword searches. We clarify cultural fit through personal dialogue. We combine the process reliability of a large consulting firm with the exclusivity of a specialized partner. Mass recruitment is completely out of the question for us.
In today's job market, these factors are crucial. Those who fail to demonstrate flexibility lose their appeal. Top talent today actively seeks roles with societal impact. We address these values right from the initial contact. This ensures that the candidate's vision aligns with your company culture. Our expertise in this area is regularly discussed in specialist publications such as Healthrelations .
Market conditions and compensation structures are assessed through ongoing dialogue with market participants. This expertise is occasionally sought by business media. For example, Handelsblatt quoted Christoph Andris on current job booms and salary trends. The article was published under the former company name ACC. It demonstrates the long-standing trust placed in our market knowledge.
In the Rx Specialty Pharma sector, ANDRIS CONSULTING fills senior management positions and high-impact specialist roles. These include Individual Contributors in Medical Affairs (MSL, Medical Advisor), Market Access or Commercial Launch Teams (Launch Excellence Manager, Senior Product Manager) whose professional expertise is crucial for the market success of a specialty product during and after the launch phase.
ANDRIS CONSULTING provides expertise in the Rx Specialty Pharma sector across all relevant indications. These include oncology and hematology, including CAR-T and antibody-drug conjugates; immunology and autoimmune diseases; rare diseases and orphan drugs; neurology and neurodegeneration; gynecology; HRT; dermatology and gastroenterology; as well as gene and cell therapy across various indications. Specific areas of focus are determined by the indication profile and pipeline strategy of each client.
In the Rx Specialty Pharma sector, ANDRIS CONSULTING's largest mandate concentration lies in three functional areas: Medical Affairs, Marketing and Launch Excellence, and Commercial Leadership and Sales. Founder Christoph Andris has been active in pharmaceutical recruiting since 2009, and ANDRIS CONSULTING was established in 2018. In these areas, ANDRIS CONSULTING has developed a deep understanding of role profiles, career paths, and compensation structures within the specialty pharmaceutical environment. This specialization enables particularly precise candidate selection and significantly reduces the time to placement.
This is a perfectly valid business question. At first glance, the success-based model seems less risky: no hiring, no costs. However, analyzing the economic incentives reveals a classic principal-agent problem. In the contingency model, the consultant bears the full cost risk. Their economic imperative is speed over thoroughness. They focus on candidates who are readily available. If the search becomes complex, their model forces them to divert resources. Your interests and theirs are asymmetrical: you want the best, the recruiter needs the fastest. The committed capital in the mandate model aligns these interests. ANDRIS CONSULTING is paid to penetrate the entire market and also activate candidates who are not actively searching. Identifying latent motivations for change and cultural fit requires resources, sensitivity, and seniority; in a pure recruitment business, this effort would simply be uneconomical. The retainer is not an additional fee, but an investment in process reliability. The cost-per-hire remains the same. The total cost of ownership is generally lower in the mandate model, provided you have the right recruitment consultant on your side.